Breathe Well Live Well
|
Genentech snags a PhII-ready IL-33 asthma/COPD drug from Amgen
FierceBiotech Genentech, though, appears to be out front with its new antibody–which Amgen had dubbed AMG 282–now headed into Phase II for asthma and COPD as investigators set out to see if they can control the diseases by shutting down the IL-33 pathway. |
View full post on asthma – Google News
|
Genentech to Present at 2015 COPD & Asthma Conference on Biomarker …
Lung Disease News Biotechnology company Genentech has been invited to present at the 11th Asthma & COPD conference, an annual event that will gather some of the most internationally prominent scientists, clinicians and industry leaders to discuss the latest findings on … |
View full post on asthma – Google News
Counsel & Heal |
Roche's Genentech Drug could treat Asthma and Allergies
Counsel & Heal According to a recent study, a new drug has the potential to treat asthma and allergies. The researchers reported that the drug manufactured by Roche Biotech's Genentech called quilizumab can treat the two health conditions by preventing the body's … |
View full post on asthma – Google News